GH Research (NASDAQ:GHRS) Posts Quarterly Earnings Results

Posted by Geri Gentry on May 16th, 2026

GH Research (NASDAQ:GHRS – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.04), FiscalAI reports.

GH Research Stock Performance

Shares of NASDAQ:GHRS opened at $21.39 on Friday. GH Research has a 52 week low of $10.66 and a 52 week high of $24.66. The company’s fifty day moving average is $17.14 and its 200-day moving average is $15.53. The company has a market capitalization of $1.33 billion, a PE ratio of -23.25 and a beta of 1.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in GHRS. Barclays PLC lifted its position in GH Research by 63.4% during the 4th quarter. Barclays PLC now owns 2,118 shares of the company’s stock worth $27,000 after buying an additional 822 shares in the last quarter. Osaic Holdings Inc. lifted its position in GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after buying an additional 2,400 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in GH Research during the 2nd quarter worth about $79,000. HRT Financial LP acquired a new position in GH Research during the 4th quarter worth about $202,000. Finally, BNP Paribas Financial Markets lifted its position in GH Research by 165.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock worth $207,000 after buying an additional 10,600 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

Wall Street Analyst Weigh In

GHRS has been the topic of a number of recent analyst reports. Citigroup reissued an “outperform” rating on shares of GH Research in a research report on Friday. HC Wainwright lifted their price target on shares of GH Research from $35.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of GH Research in a research report on Tuesday, April 21st. Guggenheim set a $34.00 target price on shares of GH Research and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Finally, Citizens Jmp decreased their price target on shares of GH Research from $42.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.00.

View Our Latest Report on GHRS

About GH Research

(Get Free Report)

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.